Native supramolecular assemblies containing collagen VI microfibrils and associated extracellular matrix proteins were isolated from Swarm rat chondrosarcoma tissue. Their composition and spatial organization were characterized by electron microscopy and immunological detection of molecular constituents. The small leucine-rich repeat (LRR) proteoglycans biglycan and decorin were bound to the N-terminal region of collagen VI. Chondroadherin, another member of the LRR family, was identified both at the N and C termini of collagen VI. Matrilin-1, -3, and -4 were found in complexes with biglycan or decorin at the N terminus. The interactions between collagen VI, biglycan, decorin, and matrilin-1 were studied in detail and revealed a biglycan/matrilin-1 or decorin/matrilin-1 complex acting as a linkage between collagen VI microfibrils and aggrecan or alternatively collagen II. The complexes between matrilin-1 and biglycan or decorin were also reconstituted in vitro. Colocalization of collagen VI and the different ligands in the pericellular matrix of cultured chondrosarcoma cells supported the physiological relevance of the observed interactions in matrix assembly.Connective tissues are characterized by an abundant extracellular matrix in which a wide variety of different proteins and proteoglycans assemble into multimolecular complexes, often in the form of networks. The fibrillar collagens are major components (for review, see Ref. 1) and, in cartilage, collagen II forms cross-striated fibrils in association with collagen IX and XI (2). Collagen VI is another member of the collagen family that distinguishes itself by containing large globular domains at its N and C termini (3-6). The molecule consists of three genetically distinct ␣-chains, ␣1(VI), ␣2(VI), and ␣3(VI). The N-terminal globular region is composed of nine or ten von Willebrand factor (vWF) 1 A-like domains derived from the ␣3-chain. Collagen VI molecules associate laterally in an antiparallel fashion into dimers that are stabilized by disulfide bridges (3, 4, 7). The dimers aggregate further into tetramers that are secreted into the extracellular matrix (7), where they join end to end into microfibrils. These subsequently form characteristic thin beaded filaments that are found in a variety of tissues (3,8,9). The formation of microfibrils was recently shown to depend on the N5 vWFA-like domain of ␣3(VI) (10). In addition to the collagens, the large hyaluronan-binding proteoglycan, aggrecan is a major constituent of the cartilage extracellular matrix. The aggrecan core protein has a molecular weight of ϳ220 kDa (11) These major constituents provide the basic organization of the extracellular matrix, while other molecules modulate its assembly and structure. The matrilins are a family of oligomeric matrix proteins containing common structural motifs such as vWFA-like domains, epidermal growth factor-like EGF modules and coiled-coil regions (reviewed in Ref. 18). Matrilin-1 (also known as cartilage matrix protein, CMP), and matrilin-3 are abundant in ca...

Matrilin-3 is a recently identified member of the superfamily of proteins containing von Willebrand factor A-like domains and is able to form hetero-oligomers with matrilin-1 (cartilage matrix protein) via a C-terminal coiled-coil domain. Full-length matrilin-3 and a fragment lacking the assembly domain were expressed in 293-EBNA cells, purified, and subjected to biochemical characterization. Recombinantly expressed full-length matrilin-3 occurs as monomers, dimers, trimers, and tetramers, as detected by electron microscopy and SDSpolyacrylamide gel electrophoresis, whereas matrilin-3, purified from fetal calf cartilage, forms homotetramers as well as hetero-oligomers of variable stoichiometry with matrilin-1. In the matrix formed by cultured chondrosarcoma cells, matrilin-3 is found in a filamentous, collagen-dependent network connecting cells and in a collagen-independent pericellular network. Affinity-purified antibodies detect matrilin-3 expression in a variety of mouse cartilaginous tissues, such as sternum, articular, and epiphyseal cartilage, and in the cartilage anlage of developing bones. It is found both inside the lacunae and in the interterritorial matrix of the resting, proliferating, hypertrophic, and calcified cartilage zones, whereas the expression is lower in the superficial articular cartilage. In trachea and in costal cartilage of adult mice, an expression was seen in the perichondrium. Furthermore, matrilin-3 is found in bone, and its expression is, therefore, not restricted to chondroblasts and chondrocytes.The matrilins constitute a recently discovered family of noncollagenous proteins (1) belonging to the von Willebrand factor A (vWFA) 1 -like domain superfamily. To date, there are four matrilins known. Matrilin-2 (2, 3) and matrilin-4 (4, 5) have a broad tissue distribution, whereas the expression of matrilin-1 (also known as cartilage matrix protein) (6 -8) and matrilin-3 (9 -11) is more restricted to skeletal tissues. The division of the family into two subgroups can also be concluded from evolutionary studies (1). The descent from a common ancestor and the divergence through duplication of whole domains indicates the possibility of the different family members providing similar functions in different tissues. The at least partially coordinated expression of matrilin-1 and -3 gains further functional significance through the recent discovery of hetero-oligomers formed by matrilin-1 and -3 in epiphyseal cartilage of fetal calf femur (12).Matrilin-3 has most features of the modular structure typical for matrilins and consists of an N-terminal vWFA-like domain, four EGF-like domains, and a C-terminal ␣-helical coiled-coil oligomerization domain (9 -11), but it lacks the second vWFAlike domain that is present in all the other matrilins. Similarly, a unique mouse matrilin-4 splice variant lacking the N-terminal vWFA-like domain was recently identified (4). In addition, matrilin-3 possesses a domain with a high content of positively charged amino acids between the N-terminal vWFA-like domain ...

No abstract

Matrilin-4 is the most recently identified member of the matrilin family of von Willebrand factor A-like domain containing extracellular matrix adapter proteins. Full-length matrilin-4 was expressed in 293-EBNA cells, purified using affinity tags, and subjected to biochemical characterization. The largest oligomeric form of recombinantly expressed full-length matrilin-4 is a trimer as shown by electron microscopy, SDS-polyacrylamide gel electrophoresis, and mass spectrometry. Proteolytically processed matrilin-4 species were also detected. The cleavage occurs in the short linker region between the second von Willebrand factor A-like domain and the coiled-coil domain leading to the release of large fragments and the formation of dimers and monomers of intact subunits still containing a trimeric coiled-coil. In immunoblots of calvaria extracts similar degradation products could be detected, indicating that a related proteolytic processing occurs in vivo. Matrilin-4 was first observed at day 7.5 post-coitum in mouse embryos. Affinity-purified antibodies detect a broad expression in dense and loose connective tissue, bone, cartilage, central and peripheral nervous systems and in association with basement membranes. In the matrix formed by cultured primary embryonic fibroblasts, matrilin-4 is found in a filamentous network connecting individual cells.

We report a process that results in the acceleration of matrix degradation in human articular cartilage, a phenomenon commonly observed in osteoarthritis (OA). The study was conducted by (1) examining the potential of collagen II in modulating the gene expression profile of primary human chondrocytes (PHCs), and (2) investigating the involvement of pro-inflammatory signaling cascades. We first tested the collagen II-dependent induction of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) in PHCs. PHCs were incubated with or without monomeric (i.e., nonfibrillar) collagen II. Cells were then analyzed by RT-PCR for the expression of MMP1, MMP3, MMP13, MMP14, and IL-1b. ELISA was used to quantify IL-6 and IL-8 release. To examine the influence of collagen II signaling, specifically the role of MAPK p38, a p38-inhibitor was added prior to collagen treatment. Changes in IkB concentration were monitored by immunoblot analysis to detect NFkB signaling. Results indicated that incubation of PHCs with collagen II did produce a dose-dependent induction of MMP1, MMP3, MMP13, MMP14, as well as cytokines IL-1b, IL-6, and IL-8. At the same time, inhibition of p38 and IkB degradation revealed that collagen II-dependent gene induction also involves MAPK p38 and NFkB signaling. Thus, we provide evidence for a collagen II-dependent feed-forward mechanism whereby collagen II induces first MMPs and pro-inflammatory cytokines and then release of collagen II fragments from mature collagen II fibers. This, in turn, induces more pro-inflammatory cytokines and MMPs, and the process is repeated, which results in the acceleration and perpetuation of cartilage matrix degradation. Keywords: collagen; chondrocytes; osteoarthritis; matrix metalloproteinases; Osteoarthritis (OA) is a chronic disease of synovial joints. Although the etiology and pathogenesis of OA are poorly understood, we do know that degradation of the extracellular matrix (ECM) in articular cartilage is a major cause of joint destruction. Cartilage degradation is mediated by matrix metalloproteinases (MMPs), principally MMP1, MMP3, and MMP13.1-4 MMP1 (collagenase-1) and MMP13 (collagenase-3) are able to cleave mature collagen fibers and initiate further collagen degradation. MMP3 (stromelysin-1) cleaves a variety of ECM components, including proteoglycans, collagens, and procollagens.5 Chondrocytes respond to various stimuli, such as pro-inflammatory cytokines or mechanical load, by their induction of MMPs. Collagen II may fulfill a similar function in that both collagen II and a synthetic 29-mer collagen peptide have recently been shown to induce MMP2, MMP3, MMP9, and MMP13 in primary bovine articular chondrocytes. 6 According to other studies, collagen II can induce MMP13 in the immortalized human chondrocyte cell line C-28/I2, which transiently expresses discoidin domain receptor-2 (DDR-2) cDNA. 4 Thus far, however, the induction of MMPs by collagen II in PHCs has not been investigated. The induction of collagenase-1 or MMP14 (membranetype MMP1, MT...

No abstract

Key Points• B-cell-specific expression of Myd88 p.L252P leads to the development of DLBCL in mice.• The Myd88 p.L252P mutation cooperates with BCL2 amplifications in ABC-DLBCL lymphomagenesis in vivo.The adaptor protein MYD88 is critical for relaying activation of Toll-like receptor signaling to NF-kB activation. MYD88 mutations, particularly the p.L265P mutation, have been described in numerous distinct B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Twenty-nine percent of activated B-cell-type DLBCL (ABC-DLBCL), which is characterized by constitutive activation of the NF-kB pathway, carry the p.L265P mutation. In addition, ABC-DLBCL frequently displays focal copy number gains affecting BCL2. Here, we generated a novel mouse model in which Cre-mediated recombination, specifically in B cells, leads to the conditional expression of Myd88 p.L252P (the orthologous position of the human MYD88 p.L265P mutation) from the endogenous locus.These mice develop a lymphoproliferative disease and occasional transformation into clonal lymphomas. The clonal disease displays the morphologic and immunophenotypical characteristics of ABC-DLBCL. Lymphomagenesis can be accelerated by crossing in a further novel allele, which mediates conditional overexpression of BCL2. Cross-validation experiments in human DLBCL samples revealed that both MYD88 and CD79B mutations are substantially enriched in ABC-DLBCL compared with germinal center B-cell DLBCL. Furthermore, analyses of human DLBCL genome sequencing data confirmed that BCL2 amplifications frequently cooccurred with MYD88 mutations, further validating our approach. Finally, in silico experiments revealed that MYD88-mutant ABC-DLBCL cells in particular display an actionable addiction to BCL2. Altogether, we generated a novel autochthonous mouse model of ABC-DLBCL that could be used as a preclinical platform for the development and validation of novel therapeutic approaches for the treatment of ABC-DLBCL. (Blood. 2016;127(22):2732-2741

We conclude that matrilin-3 is an integral component of human articular cartilage matrix and that the enhanced expression of matrilin-3 in OA may be a cellular response to the modified microenvironment in the disease.